AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.
It is a $488B healthcare company. Revenue grew 10.4% over the last year, it keeps 10¢ of every dollar of sales as profit, and its net debt equals ~3.1 years of free cash flow. It trades at 77.4× earnings — in the most expensive third of its own history.
- Website
- abbvie.com
- Location
- North Chicago, IL
- Employees
- 57 000
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong quality and moat; Valuation, Growth and Health lag behind.
Valuation34
- P/E vs own history77th pct · 5/25
- FCF yield3.7% · 12/25
- P/S7.6x · 12/25
- EV/EBITDA31.3x · 5/25
Growth31
- Revenue CAGR2.1% · 6/25
- Net income CAGR-22.2% · 0/25
- EPS CAGR ~5Y-2.9% · 0/25
- Fwd implied growth357.2% · 25/25
Profitability68
- ROIC8.0% · 5/25
- ROE95.6% · 25/25
- Net margin9.8% · 13/25
- Operating margin26.2% · 25/25
Health39
- Altman Z2.33 · 18/25
- Current ratio0.81 · 6/25
- Interest coverage3.5x · 10/25
- Net cash / debtD/A 42% · 5/25
Quality95
- Piotroski F8/9 · 25/25
- Beneish M-2.85 · 25/25
- FCF conversion289% · 25/25
- Margin stabilityσ 7.0% · 20/25
Moat88
- ROIC >12% years8/10 yrs · 20/25
- Median gross margin70.1% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 6.9% · 18/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- 2026MilestoneAbbVie struck a deal with the Trump administration to invest $100 billion in its US operations over…
- 2025AcquisitionAbbVie acquired Bretisilocin, which is under development for the treatment of major depressive…
- 2024AcquisitionAbbVie acquired ImmunoGen for $10.1 billion, aiming to expedite its entry into the ovarian cancer…
- FY2022FinancialBest year on record$11.8B net income
- 2022AcquisitionAbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of…
- FY2021FinancialRevenue crossed $50B$56.2B for the year
- 2021AcquisitionAllergan Aesthetics announced the acquisition of Soliton
- 2019AcquisitionAbbVie announced it would acquire Irish-based Allergan plc for about $63 billion
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $10B$25.6B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2015AcquisitionAbbVie acquired oncology firm Pharmacyclics and its treatment for blood cancers, ibrutinib
- 2014AcquisitionAbbVie ended its efforts to acquire Shire, which would have been one of the largest mergers and…
- 2013MilestoneIt became a public company in January 2013
- 2012MilestoneAbbVie was formed in 2012 as a corporate spin-off from Abbott Laboratories
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (72.8%)
- Revenue growing 10.4% year over year
- Strong cash conversion — FCF is 28.3% of revenue
- Piotroski F-Score 8/9 — fundamentally strong checklist
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+10.4% YoY
- Profitable — makes more than it spends$6.31B TTM
- Profit growing — earnings are higher than last year-29.0% YoY
- Generates cash — cash left after running and investing$18.2B TTM
- Debt under control — could handle its obligations~3.1y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$488B market cap
- Not printing shares — share count not ballooning — you keep your slice+6.0% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distressAltman Z 2.3 — grey
- Pays a dividend — returns cash to shareholdersyield 2.45%
- Valuation not extreme — price not wildly above earningsP/E 77.4
Peer comparisonAbbvie Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| ABBV this company | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
| AZN AstraZeneca PLC | $246.9B | 23.4 | +8.6% | 17.4% | Solid |
Head-to-head: ABBV vs LLY · ABBV vs JNJ · ABBV vs MRK
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/ABBV
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of ABBV on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $276.43 · market cap $488B.